Mesalamine Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Dosage From (Capsule, Tablets); Application (Ulcerative Colitis, Crohn's disease, Other Inflammatory Diseases)
Report Code: TIPRE00009006 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Mesalamine is used in the treatment of ulcerative colitis (a condition which causes swelling in the lining of the colon) and other inflammatory bowel diseases. It is a prescription drug and contains 5-aminosalicylic acid, which helps in reducing inflammation in the intestine.
MARKET DYNAMICS
Ulcerative colitis (UC) is a chronic disease of the GI tract that causes mucosal inflammation in the colon. The increasing prevalence of ulcerative colitis and inflammatory disorders is increasing the demand of mesalamine. Inflammatory bowel disease such as Crohn's disease and Crohn's disease affects a vast population worldwide. For instance, as per the Colitis Foundation of America, approximately 1.6 million Americans are suffering from IBD. Moreover, increasing research and development and improving healthcare expenditure in developing countries is further facilitating the growth of the market.
MARKET SCOPE
The "Global Mesalamine Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of mesalamine market with detailed market segmentation by dosage form, application, and geography. The global mesalamine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading mesalamine market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global mesalamine market is segmented on the basis of dosage from and application. Based on dosage form, the market is segmented into capsule and tablets. Based on application, the market is segmented as ulcerative colitis, Crohn's disease and other inflammatory diseases.
?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global mesalamine market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The mesalamine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting mesalamine market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the mesalamine market in these regions.
The report covers key developments in the mesalamine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from mesalamine market are anticipated to lucrative growth opportunities in the future with the rising demand for mesalamine market in the global market. Below mentioned is the list of few companies engaged in the mesalamine market.
The report also includes the profiles of key mesalamine market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Mylan N.V.
- Teva Pharmaceuticals
- Ferring B.V.
- Allergan
- Bausch Health Companies Inc
- Zydus Cadila
- COSMO PHARMACEUTICALS
- Tillotts Pharma AG
- Shire plc
- Pfizer
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Mesalamine is used in the treatment of ulcerative colitis (a condition which causes swelling in the lining of the colon) and other inflammatory bowel diseases. It is a prescription drug and contains 5-aminosalicylic acid, which helps in reducing inflammation in the intestine.
MARKET DYNAMICS
Ulcerative colitis (UC) is a chronic disease of the GI tract that causes mucosal inflammation in the colon. The increasing prevalence of ulcerative colitis and inflammatory disorders is increasing the demand of mesalamine. Inflammatory bowel disease such as Crohn's disease and Crohn's disease affects a vast population worldwide. For instance, as per the Colitis Foundation of America, approximately 1.6 million Americans are suffering from IBD. Moreover, increasing research and development and improving healthcare expenditure in developing countries is further facilitating the growth of the market.
MARKET SCOPE
The "Global Mesalamine Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of mesalamine market with detailed market segmentation by dosage form, application, and geography. The global mesalamine market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading mesalamine market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global mesalamine market is segmented on the basis of dosage from and application. Based on dosage form, the market is segmented into capsule and tablets. Based on application, the market is segmented as ulcerative colitis, Crohn's disease and other inflammatory diseases.
?
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global mesalamine market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The mesalamine market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting mesalamine market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the mesalamine market in these regions.
The report covers key developments in the mesalamine market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from mesalamine market are anticipated to lucrative growth opportunities in the future with the rising demand for mesalamine market in the global market. Below mentioned is the list of few companies engaged in the mesalamine market.
The report also includes the profiles of key mesalamine market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Mylan N.V.
- Teva Pharmaceuticals
- Ferring B.V.
- Allergan
- Bausch Health Companies Inc
- Zydus Cadila
- COSMO PHARMACEUTICALS
- Tillotts Pharma AG
- Shire plc
- Pfizer
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Mesalamine Market - By Dosage From
1.3.2 Mesalamine Market - By Application
1.3.3 Mesalamine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MESALAMINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MESALAMINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MESALAMINE MARKET - GLOBAL MARKET ANALYSIS
6.1. MESALAMINE - GLOBAL MARKET OVERVIEW
6.2. MESALAMINE - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2027 - DOSAGE FROM
7.1. OVERVIEW
7.2. DOSAGE FROM MARKET FORECASTS AND ANALYSIS
7.3. CAPSULE
7.3.1. Overview
7.3.2. Capsule Market Forecast and Analysis
7.4. TABLETS
7.4.1. Overview
7.4.2. Tablets Market Forecast and Analysis
8. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ULCERATIVE COLITIS
8.3.1. Overview
8.3.2. Ulcerative Colitis Market Forecast and Analysis
8.4. CROHN'S DISEASE
8.4.1. Overview
8.4.2. Crohn's disease Market Forecast and Analysis
8.5. OTHER INFLAMMATORY DISEASES
8.5.1. Overview
8.5.2. Other Inflammatory Diseases Market Forecast and Analysis
9. MESALAMINE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Mesalamine Market Overview
9.1.2 North America Mesalamine Market Forecasts and Analysis
9.1.3 North America Mesalamine Market Forecasts and Analysis - By Dosage From
9.1.4 North America Mesalamine Market Forecasts and Analysis - By Application
9.1.5 North America Mesalamine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Mesalamine Market
9.1.5.1.1 United States Mesalamine Market by Dosage From
9.1.5.1.2 United States Mesalamine Market by Application
9.1.5.2 Canada Mesalamine Market
9.1.5.2.1 Canada Mesalamine Market by Dosage From
9.1.5.2.2 Canada Mesalamine Market by Application
9.1.5.3 Mexico Mesalamine Market
9.1.5.3.1 Mexico Mesalamine Market by Dosage From
9.1.5.3.2 Mexico Mesalamine Market by Application
9.2. EUROPE
9.2.1 Europe Mesalamine Market Overview
9.2.2 Europe Mesalamine Market Forecasts and Analysis
9.2.3 Europe Mesalamine Market Forecasts and Analysis - By Dosage From
9.2.4 Europe Mesalamine Market Forecasts and Analysis - By Application
9.2.5 Europe Mesalamine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Mesalamine Market
9.2.5.1.1 Germany Mesalamine Market by Dosage From
9.2.5.1.2 Germany Mesalamine Market by Application
9.2.5.2 France Mesalamine Market
9.2.5.2.1 France Mesalamine Market by Dosage From
9.2.5.2.2 France Mesalamine Market by Application
9.2.5.3 Italy Mesalamine Market
9.2.5.3.1 Italy Mesalamine Market by Dosage From
9.2.5.3.2 Italy Mesalamine Market by Application
9.2.5.4 Spain Mesalamine Market
9.2.5.4.1 Spain Mesalamine Market by Dosage From
9.2.5.4.2 Spain Mesalamine Market by Application
9.2.5.5 United Kingdom Mesalamine Market
9.2.5.5.1 United Kingdom Mesalamine Market by Dosage From
9.2.5.5.2 United Kingdom Mesalamine Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Mesalamine Market Overview
9.3.2 Asia-Pacific Mesalamine Market Forecasts and Analysis
9.3.3 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Dosage From
9.3.4 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Mesalamine Market
9.3.5.1.1 Australia Mesalamine Market by Dosage From
9.3.5.1.2 Australia Mesalamine Market by Application
9.3.5.2 China Mesalamine Market
9.3.5.2.1 China Mesalamine Market by Dosage From
9.3.5.2.2 China Mesalamine Market by Application
9.3.5.3 India Mesalamine Market
9.3.5.3.1 India Mesalamine Market by Dosage From
9.3.5.3.2 India Mesalamine Market by Application
9.3.5.4 Japan Mesalamine Market
9.3.5.4.1 Japan Mesalamine Market by Dosage From
9.3.5.4.2 Japan Mesalamine Market by Application
9.3.5.5 South Korea Mesalamine Market
9.3.5.5.1 South Korea Mesalamine Market by Dosage From
9.3.5.5.2 South Korea Mesalamine Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Mesalamine Market Overview
9.4.2 Middle East and Africa Mesalamine Market Forecasts and Analysis
9.4.3 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Dosage From
9.4.4 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Mesalamine Market
9.4.5.1.1 South Africa Mesalamine Market by Dosage From
9.4.5.1.2 South Africa Mesalamine Market by Application
9.4.5.2 Saudi Arabia Mesalamine Market
9.4.5.2.1 Saudi Arabia Mesalamine Market by Dosage From
9.4.5.2.2 Saudi Arabia Mesalamine Market by Application
9.4.5.3 U.A.E Mesalamine Market
9.4.5.3.1 U.A.E Mesalamine Market by Dosage From
9.4.5.3.2 U.A.E Mesalamine Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Mesalamine Market Overview
9.5.2 South and Central America Mesalamine Market Forecasts and Analysis
9.5.3 South and Central America Mesalamine Market Forecasts and Analysis - By Dosage From
9.5.4 South and Central America Mesalamine Market Forecasts and Analysis - By Application
9.5.5 South and Central America Mesalamine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Mesalamine Market
9.5.5.1.1 Brazil Mesalamine Market by Dosage From
9.5.5.1.2 Brazil Mesalamine Market by Application
9.5.5.2 Argentina Mesalamine Market
9.5.5.2.1 Argentina Mesalamine Market by Dosage From
9.5.5.2.2 Argentina Mesalamine Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. MESALAMINE MARKET, KEY COMPANY PROFILES
11.1. MYLAN N.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. TEVA PHARMACEUTICALS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. FERRING B.V.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ALLERGAN
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BAUSCH HEALTH COMPANIES INC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ZYDUS CADILA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. COSMO PHARMACEUTICALS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TILLOTTS PHARMA AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SHIRE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Mesalamine Market - By Dosage From
1.3.2 Mesalamine Market - By Application
1.3.3 Mesalamine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MESALAMINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MESALAMINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MESALAMINE MARKET - GLOBAL MARKET ANALYSIS
6.1. MESALAMINE - GLOBAL MARKET OVERVIEW
6.2. MESALAMINE - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2027 - DOSAGE FROM
7.1. OVERVIEW
7.2. DOSAGE FROM MARKET FORECASTS AND ANALYSIS
7.3. CAPSULE
7.3.1. Overview
7.3.2. Capsule Market Forecast and Analysis
7.4. TABLETS
7.4.1. Overview
7.4.2. Tablets Market Forecast and Analysis
8. MESALAMINE MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ULCERATIVE COLITIS
8.3.1. Overview
8.3.2. Ulcerative Colitis Market Forecast and Analysis
8.4. CROHN'S DISEASE
8.4.1. Overview
8.4.2. Crohn's disease Market Forecast and Analysis
8.5. OTHER INFLAMMATORY DISEASES
8.5.1. Overview
8.5.2. Other Inflammatory Diseases Market Forecast and Analysis
9. MESALAMINE MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Mesalamine Market Overview
9.1.2 North America Mesalamine Market Forecasts and Analysis
9.1.3 North America Mesalamine Market Forecasts and Analysis - By Dosage From
9.1.4 North America Mesalamine Market Forecasts and Analysis - By Application
9.1.5 North America Mesalamine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Mesalamine Market
9.1.5.1.1 United States Mesalamine Market by Dosage From
9.1.5.1.2 United States Mesalamine Market by Application
9.1.5.2 Canada Mesalamine Market
9.1.5.2.1 Canada Mesalamine Market by Dosage From
9.1.5.2.2 Canada Mesalamine Market by Application
9.1.5.3 Mexico Mesalamine Market
9.1.5.3.1 Mexico Mesalamine Market by Dosage From
9.1.5.3.2 Mexico Mesalamine Market by Application
9.2. EUROPE
9.2.1 Europe Mesalamine Market Overview
9.2.2 Europe Mesalamine Market Forecasts and Analysis
9.2.3 Europe Mesalamine Market Forecasts and Analysis - By Dosage From
9.2.4 Europe Mesalamine Market Forecasts and Analysis - By Application
9.2.5 Europe Mesalamine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Mesalamine Market
9.2.5.1.1 Germany Mesalamine Market by Dosage From
9.2.5.1.2 Germany Mesalamine Market by Application
9.2.5.2 France Mesalamine Market
9.2.5.2.1 France Mesalamine Market by Dosage From
9.2.5.2.2 France Mesalamine Market by Application
9.2.5.3 Italy Mesalamine Market
9.2.5.3.1 Italy Mesalamine Market by Dosage From
9.2.5.3.2 Italy Mesalamine Market by Application
9.2.5.4 Spain Mesalamine Market
9.2.5.4.1 Spain Mesalamine Market by Dosage From
9.2.5.4.2 Spain Mesalamine Market by Application
9.2.5.5 United Kingdom Mesalamine Market
9.2.5.5.1 United Kingdom Mesalamine Market by Dosage From
9.2.5.5.2 United Kingdom Mesalamine Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Mesalamine Market Overview
9.3.2 Asia-Pacific Mesalamine Market Forecasts and Analysis
9.3.3 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Dosage From
9.3.4 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Mesalamine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Mesalamine Market
9.3.5.1.1 Australia Mesalamine Market by Dosage From
9.3.5.1.2 Australia Mesalamine Market by Application
9.3.5.2 China Mesalamine Market
9.3.5.2.1 China Mesalamine Market by Dosage From
9.3.5.2.2 China Mesalamine Market by Application
9.3.5.3 India Mesalamine Market
9.3.5.3.1 India Mesalamine Market by Dosage From
9.3.5.3.2 India Mesalamine Market by Application
9.3.5.4 Japan Mesalamine Market
9.3.5.4.1 Japan Mesalamine Market by Dosage From
9.3.5.4.2 Japan Mesalamine Market by Application
9.3.5.5 South Korea Mesalamine Market
9.3.5.5.1 South Korea Mesalamine Market by Dosage From
9.3.5.5.2 South Korea Mesalamine Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Mesalamine Market Overview
9.4.2 Middle East and Africa Mesalamine Market Forecasts and Analysis
9.4.3 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Dosage From
9.4.4 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Mesalamine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Mesalamine Market
9.4.5.1.1 South Africa Mesalamine Market by Dosage From
9.4.5.1.2 South Africa Mesalamine Market by Application
9.4.5.2 Saudi Arabia Mesalamine Market
9.4.5.2.1 Saudi Arabia Mesalamine Market by Dosage From
9.4.5.2.2 Saudi Arabia Mesalamine Market by Application
9.4.5.3 U.A.E Mesalamine Market
9.4.5.3.1 U.A.E Mesalamine Market by Dosage From
9.4.5.3.2 U.A.E Mesalamine Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Mesalamine Market Overview
9.5.2 South and Central America Mesalamine Market Forecasts and Analysis
9.5.3 South and Central America Mesalamine Market Forecasts and Analysis - By Dosage From
9.5.4 South and Central America Mesalamine Market Forecasts and Analysis - By Application
9.5.5 South and Central America Mesalamine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Mesalamine Market
9.5.5.1.1 Brazil Mesalamine Market by Dosage From
9.5.5.1.2 Brazil Mesalamine Market by Application
9.5.5.2 Argentina Mesalamine Market
9.5.5.2.1 Argentina Mesalamine Market by Dosage From
9.5.5.2.2 Argentina Mesalamine Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. MESALAMINE MARKET, KEY COMPANY PROFILES
11.1. MYLAN N.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. TEVA PHARMACEUTICALS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. FERRING B.V.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ALLERGAN
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BAUSCH HEALTH COMPANIES INC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ZYDUS CADILA
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. COSMO PHARMACEUTICALS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. TILLOTTS PHARMA AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SHIRE PLC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. PFIZER
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Mylan N.V.
2. Teva Pharmaceuticals
3. Ferring B.V.
4. Allergan
5. Bausch Health Companies Inc
6. Zydus Cadila
7. COSMO PHARMACEUTICALS
8. Tillotts Pharma AG
9. Shire plc
10. Pfizer
1. Mylan N.V.
2. Teva Pharmaceuticals
3. Ferring B.V.
4. Allergan
5. Bausch Health Companies Inc
6. Zydus Cadila
7. COSMO PHARMACEUTICALS
8. Tillotts Pharma AG
9. Shire plc
10. Pfizer